排序方式: 共有66条查询结果,搜索用时 218 毫秒
1.
2.
Lioure B Béné MC Pigneux A Huynh A Chevallier P Fegueux N Blaise D Witz B Delain M Cornillon J Luquet I Blanchet O Cornillet-Lefebvre P Carré M Hunault M Larosa F Lamy T Randriamalala E Ojeda-Uribe M Berthou C Fornecker L Harousseau JL Bouscary D Ifrah N Cahn JY;GOELAMS 《Blood》2012,119(12):2943-2948
The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger patients, while the older ones received a consolidation course, followed by peripheral blood allo-HSCT using RIC. The incidence of grade II-IV acute GVHD, was 51.9% (95% confidence interval [CI]: 42.1-61.8) and 11.3% (1.6-21.2) after myeloablative or RIC, respectively (P < .0001) and that of chronic GVHD 45.8% (95% CI: 34.8-56.7) and 41.7% (24.7-58.6; NS). Cumulative incidence of nonrelapse mortality at 108 months was 15.8% (95% CI: 9.8-23.2) for myeloablative, and 6.5% (0.2-16.2) for RIC (NS). CI of relapse at 108 months was 21.7% (95% CI: 13.9-28.6) and 28.6% (16.5-43.4; NS). Overall survival at 108 months was 63.4% (95% CI: 54.6-72.2) and 65.8% (52.2-72.2), respectively, after myeloablative or RIC (NS). RIC peripheral blood stem cell allo-HSCT is prospectively feasible for patients between the ages of 51 and 60 years without excess of relapse or nonrelapse mortality, and compares favorably with myeloablative marrow allo-HSCT proposed to younger patients. 相似文献
3.
Coombes RC Kilburn LS Snowdon CF Paridaens R Coleman RE Jones SE Jassem J Van de Velde CJ Delozier T Alvarez I Del Mastro L Ortmann O Diedrich K Coates AS Bajetta E Holmberg SB Dodwell D Mickiewicz E Andersen J Lønning PE Cocconi G Forbes J Castiglione M Stuart N Stewart A Fallowfield LJ Bertelli G Hall E Bogle RG Carpentieri M Colajori E Subar M Ireland E Bliss JM;Intergroup Exemestane Study 《Lancet》2007,369(9561):559-570
4.
5.
Casula M Colombino M Satta MP Cossu A Lissia A Budroni M Simeone E Calemma R Loddo C Caracò C Mozzillo N Daponte A Comella G Canzanella S Guida M Castello G Ascierto PA Palmieri G;Italian Melanoma Intergroup 《European journal of cancer (Oxford, England : 1990)》2007,43(1):137-143
Clinical predictors for germline mutations of candidate genes in large clinic based population of patients with cutaneous malignant melanoma (CMM) are widely awaited. Using denaturing high-performance liquid chromatography (DHPLC) analysis and DNA sequencing, 557 consecutively-collected CMM patients originating from South Italy were screened for CDKN2A germline mutations; subsets of them were screened for mutations in the BRAF and BRCA2 genes. Seven CDKN2A mutations were detected in 14 (2.5%) CMM patients. Relative risk of carrying a CDKN2A mutation for CMM patients was demonstrated to significantly increase with the presence of familial recurrence of melanoma (risk ratio (RR)=6.31; p=0.0009), multiple primary melanomas (RR=3.43; p=0.0014), and early onset age (RR=4.56; p=0.0026). All CDKN2A mutations were observed in non-Sardinian patients (14/441; 3.2%), whereas BRAF and BRCA2 genes were found mutated in Sardinian patients (3/116; 2.6%). Such indicators of the presence of CDKN2A mutations will be useful in counselling patients about undergoing genetic testing. Our findings strongly suggest that mutation rates of candidate cancer genes may deeply vary among CMM patients from different geographical areas. 相似文献
6.
Chee Khoon Lee PhD Michael L. Friedlander PhD Angelina Tjokrowidjaja MPH Jonathan A. Ledermann MD Robert L. Coleman MD Mansoor R. Mirza MD Ursula A. Matulonis MD Eric Pujade-Lauraine PhD Ralph Bloomfield MSc Sandra Goble MS Ping Wang PhD Rosalind M. Glasspool PhD Clare L. Scott PhD the Gynecologic Cancer Intergroup Meta-Analysis Committee 《Cancer》2021,127(14):2432-2441
7.
8.
Jaccard A Gachard N Marin B Rogez S Audrain M Suarez F Tilly H Morschhauser F Thieblemont C Ysebaert L Devidas A Petit B de Leval L Gaulard P Feuillard J Bordessoule D Hermine O;GELA GOELAMS Intergroup 《Blood》2011,117(6):1834-1839
Extranodal NK/T-cell lymphoma, nasal type, is a rare and highly aggressive disease with a grim prognosis. No therapeutic strategy is currently identified in relapsing patients. We report the results of a French prospective phase II trial of an L-asparaginase-containing regimen in 19 patients with relapsed or refractory disease treated in 13 centers. Eleven patients were in relapse and 8 patients were refractory to their first line of treatment. L-Asparaginase-based treatment yielded objective responses in 14 of the 18 evaluable patients after 3 cycles. Eleven patients entered complete remission (61%), and only 4 of them relapsed. The median overall survival time was 1 year, with a median response duration of 12 months. The main adverse events were hepatitis, cytopenia, and allergy. The absence of antiasparaginase antibodies and the disappearance of Epstein-Barr virus serum DNA were significantly associated with a better outcome. These data confirm the excellent activity of L-asparaginase-containing regimens in extranodal NK/T-cell lymphoma. L-Asparaginase-based treatment should thus be considered for salvage therapy, especially in patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma warrants evaluation in prospective trials. This trial is registered at www.clinicaltrials.gov as #NCT00283985. 相似文献
9.
Houot R Le Gouill S Ojeda Uribe M Mounier C Courby S Dartigeas C Bouabdallah K Alexis Vigier M Moles MP Tournilhac O Arakelyan N Rodon P El Yamani A Sutton L Fornecker L Assouline D Harousseau JL Maisonneuve H Caulet-Maugendre S Gressin R;French GOELAMS group 《Annals of oncology》2012,23(6):1555-1561
BackgroundThere is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL.Patients and methodsPatients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C.ResultsThirty-nine patients were enrolled. Median age was 72 years (65–80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity.ConclusionThe bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL. 相似文献